Glaukos Corporation develops therapies for chronic eye diseases, focusing on advancing the standard of care in ophthalmology. The company offers treatments for glaucoma and cornea cross-linking interventions to address progressive keratoconus. Glaukos reinvests a significant portion of its net sales into research and development to create new solutions for patients.
- Website
- www.glaukos.com
- Issuer profile
- All listings